These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 28390942)
1. Fluorinated tranylcypromine analogues as inhibitors of lysine-specific demethylase 1 (LSD1, KDM1A). Borrello MT; Schinor B; Bartels K; Benelkebir H; Pereira S; Al-Jamal WT; Douglas L; Duriez PJ; Packham G; Haufe G; Ganesan A Bioorg Med Chem Lett; 2017 May; 27(10):2099-2101. PubMed ID: 28390942 [TBL] [Abstract][Full Text] [Related]
2. Synthesis of Carboxamide-Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia. Teresa Borrello M; Benelkebir H; Lee A; Hin Tam C; Shafat M; Rushworth SA; Bowles KM; Douglas L; Duriez PJ; Bailey S; Crabb SJ; Packham G; Ganesan A ChemMedChem; 2021 Apr; 16(8):1316-1324. PubMed ID: 33533576 [TBL] [Abstract][Full Text] [Related]
3. Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors. Benelkebir H; Hodgkinson C; Duriez PJ; Hayden AL; Bulleid RA; Crabb SJ; Packham G; Ganesan A Bioorg Med Chem; 2011 Jun; 19(12):3709-16. PubMed ID: 21382717 [TBL] [Abstract][Full Text] [Related]
4. Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation. Sun K; Peng JD; Suo FZ; Zhang T; Fu YD; Zheng YC; Liu HM Bioorg Med Chem Lett; 2017 Nov; 27(22):5036-5039. PubMed ID: 29037950 [TBL] [Abstract][Full Text] [Related]
5. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1. Lynch JT; Cockerill MJ; Hitchin JR; Wiseman DH; Somervaille TC Anal Biochem; 2013 Nov; 442(1):104-6. PubMed ID: 23911524 [TBL] [Abstract][Full Text] [Related]
6. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation. Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189 [TBL] [Abstract][Full Text] [Related]
7. Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model. Trifirò P; Cappa A; Brambillasca S; Botrugno OA; Cera MR; Zuffo RD; Dessanti P; Meroni G; Thaler F; Villa M; Minucci S; Mercurio C; Varasi M; Vianello P Future Med Chem; 2017 Jul; 9(11):1161-1174. PubMed ID: 28722470 [TBL] [Abstract][Full Text] [Related]
8. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors. Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059 [TBL] [Abstract][Full Text] [Related]
9. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860 [TBL] [Abstract][Full Text] [Related]
10. Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation. Fioravanti R; Romanelli A; Mautone N; Di Bello E; Rovere A; Corinti D; Zwergel C; Valente S; Rotili D; Botrugno OA; Dessanti P; Vultaggio S; Vianello P; Cappa A; Binda C; Mattevi A; Minucci S; Mercurio C; Varasi M; Mai A ChemMedChem; 2020 Apr; 15(7):643-658. PubMed ID: 32003940 [TBL] [Abstract][Full Text] [Related]
11. Novel Tranylcypromine/Hydroxylcinnamic Acid Hybrids as Lysine-Specific Demethylase 1 Inhibitors with Potent Antitumor Activity. Han Y; Wu C; Lv H; Liu N; Deng H Chem Pharm Bull (Tokyo); 2015; 63(11):882-9. PubMed ID: 26521853 [TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment. Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602 [TBL] [Abstract][Full Text] [Related]
13. Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors. Huang MJ; Guo JW; Fu YD; You YZ; Xu WY; Song TY; Li R; Chen ZT; Huang LH; Liu HM Bioorg Med Chem Lett; 2021 Jun; 41():127993. PubMed ID: 33775841 [TBL] [Abstract][Full Text] [Related]
14. Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A. Vianello P; Botrugno OA; Cappa A; Ciossani G; Dessanti P; Mai A; Mattevi A; Meroni G; Minucci S; Thaler F; Tortorici M; Trifiró P; Valente S; Villa M; Varasi M; Mercurio C Eur J Med Chem; 2014 Oct; 86():352-63. PubMed ID: 25173853 [TBL] [Abstract][Full Text] [Related]
15. Development and Structural Evaluation of N-Alkylated trans-2-Phenylcyclopropylamine-Based LSD1 Inhibitors. Niwa H; Sato S; Handa N; Sengoku T; Umehara T; Yokoyama S ChemMedChem; 2020 May; 15(9):787-793. PubMed ID: 32166890 [TBL] [Abstract][Full Text] [Related]
16. Towards the development of activity-based probes for detection of lysine-specific demethylase-1 activity. Ourailidou ME; Lenoci A; Zwergel C; Rotili D; Mai A; Dekker FJ Bioorg Med Chem; 2017 Feb; 25(3):847-856. PubMed ID: 27989416 [TBL] [Abstract][Full Text] [Related]
17. 4-Hydroxy-3-methylbenzofuran-2-carbohydrazones as novel LSD1 inhibitors. He X; Gao Y; Hui Z; Shen G; Wang S; Xie T; Ye XY Bioorg Med Chem Lett; 2020 May; 30(10):127109. PubMed ID: 32201021 [TBL] [Abstract][Full Text] [Related]
18. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. Binda C; Valente S; Romanenghi M; Pilotto S; Cirilli R; Karytinos A; Ciossani G; Botrugno OA; Forneris F; Tardugno M; Edmondson DE; Minucci S; Mattevi A; Mai A J Am Chem Soc; 2010 May; 132(19):6827-33. PubMed ID: 20415477 [TBL] [Abstract][Full Text] [Related]
19. Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. Vianello P; Botrugno OA; Cappa A; Dal Zuffo R; Dessanti P; Mai A; Marrocco B; Mattevi A; Meroni G; Minucci S; Stazi G; Thaler F; Trifiró P; Valente S; Villa M; Varasi M; Mercurio C J Med Chem; 2016 Feb; 59(4):1501-17. PubMed ID: 26702542 [TBL] [Abstract][Full Text] [Related]
20. Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B. Gooden DM; Schmidt DM; Pollock JA; Kabadi AM; McCafferty DG Bioorg Med Chem Lett; 2008 May; 18(10):3047-51. PubMed ID: 18242989 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]